+

WO2004083195A1 - Composes derives de benzothiazole, compositions et utilisations - Google Patents

Composes derives de benzothiazole, compositions et utilisations Download PDF

Info

Publication number
WO2004083195A1
WO2004083195A1 PCT/US2004/007797 US2004007797W WO2004083195A1 WO 2004083195 A1 WO2004083195 A1 WO 2004083195A1 US 2004007797 W US2004007797 W US 2004007797W WO 2004083195 A1 WO2004083195 A1 WO 2004083195A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
amyloid
brain
tissue
alkyl
Prior art date
Application number
PCT/US2004/007797
Other languages
English (en)
Inventor
William E. Klunk
Jr. Chester A. Mathis
Yanming Wang
Original Assignee
University Of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/388,173 external-priority patent/US7270800B2/en
Priority claimed from US10/645,847 external-priority patent/US20050043523A1/en
Priority to EP04720788A priority Critical patent/EP1611115B1/fr
Priority to AU2004221897A priority patent/AU2004221897B2/en
Priority to BRPI0408274A priority patent/BRPI0408274B8/pt
Priority to CNA2004800125035A priority patent/CN1784392A/zh
Priority to JP2006507179A priority patent/JP4875487B2/ja
Priority to DK04720788.1T priority patent/DK1611115T3/da
Priority to SI200431952T priority patent/SI1611115T1/sl
Application filed by University Of Pittsburgh filed Critical University Of Pittsburgh
Priority to PL04720788T priority patent/PL1611115T3/pl
Priority to ES04720788T priority patent/ES2393921T3/es
Publication of WO2004083195A1 publication Critical patent/WO2004083195A1/fr
Priority to NO20054674A priority patent/NO330861B1/no
Priority to HK06107502.0A priority patent/HK1086270A1/xx
Priority to AU2011200667A priority patent/AU2011200667B2/en
Priority to NO20110980A priority patent/NO20110980L/no
Priority to FR15C0005C priority patent/FR15C0005I2/fr
Priority to NO2015005C priority patent/NO2015005I1/no
Priority to CY2015007C priority patent/CY2015007I1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention relates to thioflavin compounds and specific derivatives that are suitable for imaging amyloid deposits in living patients. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease with thioflavin derivatives. The present invention also relates to therapeutic uses for such compounds.
  • AD Alzheimer's Disease
  • a typical Alzheimer's neuritic plaque comprises dystrophic neurites surrounding a core of amyloid material.
  • the principal component of the amyloid core is a protein called amyloid-beta (A ⁇ ).
  • AD Alzheimer's disease
  • NP neuritic plaques
  • NFT neurofibrillary tangles
  • neuronal loss along with a variety of other findings.
  • Post-mortem slices of brain tissue of victims of Alzheimer's disease exhibit the presence of amyloid in the form of proteinaceous extracellular cores of the neuritic plaques that are characteristic of AD.
  • amyloid cores of these neuritic plaques are composed of a protein called the ⁇ - amyloid (A ⁇ ) that is arranged in a predominately beta-pleated sheet configuration.
  • a ⁇ ⁇ - amyloid
  • Neuritic plaques are an early and invariant aspect of the disease. Mann et al, J. Neurol. Sci. 89: 169; Mann, Mech. Ageing Dev. 31: 213 (1985); Terry et al, J. Neuropathol Exp. Neurol 46: 262 (1987).
  • a ⁇ probably occurs long before clinical symptoms are noticeable.
  • the currently recommended "minimum microscopic criteria" for the diagnosis of AD is based on the number of neuritic plaques found in brain. Khachaturian, Arch. Neurol, supra (1985). Assessment of neuritic plaque counts must be delayed until after death, however.
  • Amyloid-containing neuritic plaques are a prominent feature of selective areas of the brain in AD as well as Down's Syndrome and in persons homozygous for the apolipoprotein E4 allele who are very likely to develop AD.
  • Corder et al Science 261: 921 (1993); Divry, P., J. Neurol Psych. 27: 643-657 (1927); Wisniewski et al, in Zimmerman, H.M. (ed.): PROGRESS IN NEUROPATHOLOGY (Grune and Stratton, N.Y. 1973) pp. 1-26.
  • AD Alzheimer's disease
  • research efforts to develop methods for diagnosing Alzheimer's disease in vivo include (1) genetic testing, (2) immunoassay methods and (3) imaging techniques.
  • Evidence that abnormalities in A ⁇ metabolism are necessary and sufficient for the development of AD is based on the discovery of point mutations in the A ⁇ precursor protein in several rare families with an autosomal dominant form of AD. Hardy, Nature Genetics 1 : 233 (1992); Hardy et al, Science 256: 184 (1992). These mutations occur near the N- and C- terminal cleavage points necessary for the generation of A ⁇ from its precursor protein. St.
  • This gene may account for up to 70% of early-onset autosomal dominant AD. Preliminary data suggests that this chromosome 14 mutation causes an increase in the production of A ⁇ . Scheuner et al, Soc. Neurosci. Abstr. 21 : 1500 (1995). A mutation on a very similar gene has been identified on chromosome 1 in Volga German kindreds with early-onset AD. Levy- Lahad et al, Science 269: 973-977 (1995).
  • Immunoassay methods have been developed for detecting the presence of neurochemical markers in AD patients and to detect an AD related amyloid protein in cerebral spinal fluid.
  • These methods for diagnosing AD have not been proven to detect AD in all patients, particularly at early stages of the disease and are relatively invasive, requiring a spinal tap.
  • attempts have been made to develop monoclonal antibodies as probes for imaging of A ⁇ . Majocha et al, J.
  • Neuritic plaques and neurofibrillary tangles are the two most characteristic pathological hallmarks of AD. Klunk and Abraham, Psychiatric Development, 6:121-152 (1988). Plaques occur earliest in neocortex where they are relatively evenly distributed. Thai et ah, Neurology 58:1791-1800 (2002). Tangles appear first in limbic areas such as the transentorhinal cortex and progress in a predictable topographic pattern to the neocortex. Braak and Braak, Ada Neuropathologica 82:239-259 (1991). Arnold et al. mapped the distribution of NFT and neuritic plaques in the brains of patients with AD.
  • Arriagada et al studied the topographic distribution of AD- type pathologic changes in the brains of presumed nondemented elderly individuals. Their observations suggest that most individuals over the age of 55 have at least a few NFT and plaques. Immunohistochemically defined subtypes of SP had distinct patterns of distribution with A ⁇ -immunoreactive plaques present in neocortical areas much greater than limbic areas and Alz-50 immunoreactive plaques being infrequent and limited to those areas that contain Alz-50-positive neurons and NFT. These patterns suggested a commonality in the pathologic processes that lead to NFT and SP in both aging and AD.
  • a ⁇ amyloid-beta
  • ⁇ -amyloidosis is relatively specific to AD and closely related disorders; Selkoe, Trends in Neurosciences 16:403-409 (1993); 3) A ⁇ is toxic to cultured neurons, Yankner NeurobiolAging 13:615-616 (1992); Mattson et al, J. Neuroscience 12:376-389 (1992); Shearman et al, Proc.Natl.Acad.Sci. USA 91:1470-1474 (1994), a toxicity that appears to be dependent on ⁇ -sheet secondary structure and aggregation into at least oligomers. Lambert et al. Proc.NatlAcad.Scl USA 95:6448-6453 (1989) ; Pike et al, J.
  • AD amyloid precursor protein
  • amyloid-binding compounds will have therapeutic potential in AD and type 2 diabetes mellitus. Morphological reactions including, reactive astrocytosis, dystrophic neurites, activated microglia cells, synapse loss, and full complement activation found around neuritic plaques all signify that neurotoxic and cell degenerative processes are occurring in the areas adjacent to these A ⁇ deposits. Joachim et al., Am. J. Pathol. 135: 309 (1989); Masliah et al, loc. cit. 137: 1293 (1990); Lue and Rogers, Dementia 3: 308 (1992). A ⁇ -induced neurotoxicity and cell degeneration has been reported in a number of cell types in vitro.
  • Thioflavin T is a basic dye first described as a selective amyloid dye in 1959 by Nassar and Culling, Arch. Pathol. 68: 487 (1959). Schwartz et al, Zbl Path. 106: 320 (1964), first demonstrated the use of Thioflavin S, an acidic dye, as an amyloid dye in 1964. The properties of both Thioflavin T and Thioflavin S have since been studied in detail. Kelenyi, J. Histochem. Cytochem. 15: 172 (1967); Burns et al, J. Path. Bad 94:337 (1967); Guntern et al, Experientia 48: 8 (1992); LeNine, Meth. Enzymol 309: 274 (1999).
  • Thioflavin S commonly is used in the post-mortem study of amyloid deposition in AD brain where it has been shown to be one of the most sensitive techniques for demonstrating senile plaques. Nallet et al, A a Neuropathol 83: 170 (1992). Thioflavin T has been frequently used as a reagent to study the aggregation of soluble amyloid proteins into beta-sheet fibrils. LeNine, Prot. Sci. 2: 404 (1993). Quaternary amine derivatives related to Thioflavin T have been proposed as amyloid imaging agents, although no evidence ofbrain uptake of these agents has been presented. Caprathe et al, U.S. Patent No. 6,001,331.
  • Imaging techniques such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), are effective in monitoring the accumulation of amyloid deposits in the brain and correlating it to the progression of AD.
  • PET positron emission tomography
  • SPECT single photon emission computed tomography
  • the application of these techniques requires the development of radioligands that readily enter the brain and selectively bind to amyloid deposits in vivo. The inability to assess amyloid deposition in AD until after death impedes the study of this devastating illness.
  • a method of quantifying amyloid deposition before death is needed both as a diagnostic tool in mild or clinically confusing cases as well as in monitoring the effectiveness of therapies targeted at preventing A ⁇ deposition. Therefore, it remains of utmost importance to develop a safe and specific method for diagnosing AD before death by imaging amyloid in brain parenchyma in vivo. Even though various attempts have been made to diagnose AD in vivo, currently, there are no antemortem probes for brain amyloid. No method has utilized a high affinity probe for amyloid that has low toxicity, can cross the blood-brain barrier, and binds more effectively to AD brain than to normal brain in order to identify AD amyloid deposits in brain before a patient's death. Thus, no in vivo method for AD diagnosis has been demonstrated to meet these criteria.
  • amyloid binding compounds that are non-toxic and can cross the blood-brain barrier, and, consequently, can be used in diagnostics.
  • the present inventors have determined that varying substitution in different positions can increase binding affinity depending upon position of the substituent.
  • amyloid-imaging agents that exhibit high affinity for amyloid deposits and high permeability across the blood-brain barrier.
  • Extensive in vitro and in vivo studies of these amyloid-imaging agents suggest that they specifically bind to amyloid deposits at concentrations typical of those achieved during positron emission tomography studies.
  • non-specific binding of the amyloid-imaging compounds is low, even in control brains devoid of amyloid deposits. At nanomolar concentration, these compounds appear not to bind to neurofibrillary tangles.
  • the compounds useful for this purpose are according to the following formula: wherein Z is S, NR', O or C(R') 2 in which case the tautomeric form of the heterocyclic ring may become an indole in which R' is H or a lower alkyl group:
  • Y is NR R 2 , OR 2 , or SR 2
  • R 1 is hydrogen, -OH, -NO 2 , -CN, -COOR, -OCH 2 OR, C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 - C 6 alkynyl, C C ⁇ alkoxy or halo, wherein one or more of the atoms of R 1 may be a radiolabeled atom;
  • R is Ci-C 6 alkyl, wherein one or more of the carbon atoms may be a radiolabeled atom;
  • R 2 is hydrogen, a non-radioactive halo or a radioactive halo
  • R 3 is hydrogen, C ⁇ -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl;
  • R 4 is hydrogen, Ci-C ⁇ alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, wherein the alkyl, alkenyl or alkynyl comprises a radioactive carbon or is substituted with a radioactive halo when R 2 is hydrogen or a non-radioactive halo; provided that when R 1 is hydrogen or -OH, R 2 is hydrogen and R 4 is - ⁇ CH 3 , then R 3 is C 2 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl; and further provided that when R 1 is hydrogen, R 2 hydrogen and R 4 is -CH 2 CH 2 CH 2 18 F, then R 3 is C 2 -C 6 alkyl, C -C 6 alkenyl or C 2 -C 6 alkynyl.
  • Another embodiment relates to compounds selected from the group consisting of structurestl-45, which are useful in the disclosed methods:
  • the amyloid binding compounds of the invention bind to A ⁇ with a dissociation constant (K D ) between 0.0001 and lO.O ⁇ M when measured by binding to synthetic A ⁇ peptide or Alzheimer's Disease brain tissue.
  • K D dissociation constant
  • Another embodiment of the invention relates to a method for synthesizing the amyloid binding compounds of the present invention having at least one of the substituents selected from the group consisting of I, I, I, Br, Br, F, and F, comprising the step of labeling the amyloid binding compound wherein at least one of the substituents is a tri-alkyl tin, by reaction of the compound with a I, I, I, Br, Br, F, or F containing substance.
  • a further embodiment of the present invention relates to a pharmaceutical composition for in vivo imaging of amyloid deposits, comprising (a) an amyloid binding compound of the present invention and (b) a pharmaceutically acceptable carrier.
  • an in vivo method for detecting amyloid deposits in a subject comprising the steps of: (a) administering a detectable quantity of a pharmaceutical composition comprising the labeled amyloid binding compound, and detecting the binding of the compound to amyloid deposit in the subject.
  • the amyloid deposit is located in the brain of a subject.
  • the subject is suspected of having a disease or syndrome selected from the group consisting of Alzheimer's Disease, familial Alzheimer's Disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.
  • the detecting is selected from the group consisting of gamma imaging, magnetic resonance imaging and magnetic resonance spectroscopy.
  • the gamma imaging is either PET or SPECT.
  • the pharmaceutical composition is administered by intravenous injection.
  • the ratio of (i) binding of the compound to a brain area other than the cerebellum to (ii) binding of the compound to the cerebellum, in a subject is compared to the ratio in a normal subject.
  • the detecting of amyloid deposits in vivo is used in the diagnosis of Alzheimer's disease.
  • Another embodiment relates to a method of detecting amyloid deposits in biopsy or post-mortem human or animal tissue comprising the steps of: (a) incubating formalin-fixed or fresh-frozen tissue with a solution of an amyloid binding compound of the present invention to form a labeled deposit and then, (b) detecting the labeled deposits.
  • the solution is composed of 25-100% ethanol, with the remainder of the solution being water, wherein the solution is saturated with an amyloid binding compound according to the present invention.
  • the solution is composed of an aqueous buffer (such as tris or phosphate) containing 0-50% ethanol, wherein the solution contains 0.0001 to 100 ⁇ M of an amyloid binding compound according to the present invention.
  • the detecting is effected by microscopic techniques selected from the group consisting of bright- field, fluorescence, laser-confocal, and cross-polarization microscopy.
  • a further embodiment relates to a method of quantifying the amount of amyloid in biopsy or post-mortem tissue comprising the steps of: a) incubating a radiolabeled derivative of an amyloid binding compound of the present invention with a homogenate of biopsy or post-mortem tissue, b) separating the tissue-bound from the tissue-unbound radiolabeled derivative of an amyloid binding compound of the present invention, c) quantifying the tissue-bound radiolabeled derivative of an amyloid binding compound of the present invention, and d) converting the units of tissue-bound radiolabeled derivative of an amyloid binding compound of the present invention to units of micrograms of amyloid per 100 mg of tissue by comparison with a standard.
  • Another embodiment relates to a method of distinguishing an Alzheimer's disease brain from a normal brain comprising the steps of: a) obtaining tissue from (i) the cerebellum and (ii) another area of the same brain other than the cerebellum, from normal subjects and from subjects suspected of having Alzheimer's disease; b) incubating the tissues with a radiolabeled derivative of a thioflavin amyloid binding compounds according to the present invention so that amyloid in the tissue binds with the radiolabeled derivative of an amyloid binding compound of the present invention; c) quantifying the amount of amyloid bound to the radiolabeled derivative of an amyloid binding compound of the present invention according to the above recited method; d) calculating the ratio of the amount of amyloid in the area of the brain other than the cerebellum to the amount of amyloid in the cerebellum; e) comparing the ratio for amount of amyloid in the tissue from normal subjects with ratio for amount of amyloid in tissue from subjects suspected of having Alzheimer's disease
  • Another embodiment of the present invention relates to compounds of the present invention which are useful in binding specifically to amyloid deposits over neurofibrillary tangles.
  • Another embodiment relates to a method of selectively binding to amyloid plaques but not to neurofibrillary tangles in vivo brain tissue which contains both by administering an effective amount of a compound of the present invention so that blood concentration of the administered compound remains below 10 nM in vivo.
  • Yet another embodiment relates to novel compounds of the present invention, wherein at least one of the atoms of the formulae is replaced with a radiolabel, in particular, wherein said radiolabel is ⁇ C.
  • M* is 99m Tc.
  • Another embodiment relates to use of one of the compounds of formulae 1-45 or a compound of Formula I for the diagnosis of Alzheimer's disease in a patient in need thereof.
  • Another embodiment relates to the use of one of the compounds of formulae 1-45 or a compound of Formula I for the preparation of a medicament for diagnosis of Alzheimer's disease in a patient in need thereof.
  • Figure 1 Shows the structures of a Thioflavin S and Thioflavin T;
  • Figure 2 Shows the structures of two thioflavin derivatives according to the invention
  • Figure 3 Shows four serial sections of fluorescent dyed brain frontal cortex of an AD patient
  • Figure 4 Shows proposed sites of binding of Chrysamine G and Thioflavin T in ⁇ -sheet fibrils
  • Figure 5 Shows competition assay using Chrysamine G, Thioflavin S and Thioflavin T, and derivatives of the present invention (BTA-0, BTA- 1 and BTA-2);
  • Figure 6 Shows time course radioactivity in the frontal cortex of baboons injected with labeled BTA-1, 6-MeO-BTA-l and 6-Me-BTA-l; and
  • Figure 7 Shows a tranverse positron emission tomography image of two levels of baboon brain following i.v. injection of [N-methyl- u C]BTA-l .
  • Figure 8 Shows post-mortem sections of human and transgenic mouse brain stained with a derivative of the present invention (BTA-1).
  • Figure 9 Shows in vivo labeling of amyloid plaques and vascular amyloid stained by a derivative of the present invention (BTA-1) in living transgenic mice imaged with multiphoton microscopy.
  • Figure 10A Shows a data comparison of [ 3 H]binding to homogenates from a control brain, Alzheimer's disease brain and non- Alzheimer's disease dementia brain.
  • Figure 10B Shows data ratio from a comparison of the frontal cortex and cerebellum for each individual brain in a control brain, Alzheimer's disease brain and non- Alzheimer's disease dementia brain.
  • Figure 11 A-F Shows the specificity of the inventive compounds for amyloid plaques over neurofibrillary tangles, where A and B show the entorhinal cortex, C and D show the frontal cortex and E and F show the cerebellum of a Braak stage II control crain.
  • Figure 12 Table showing [ 3 H] BTA-1 binding to specified areas of a Braak II Control Brain and a Braak VI AD Brain (AD02).
  • Figure 13 Shows a Scratchard plot of the binding of [ 3 H] BTA-1 to homogenates from AD frontal gray matter and underlying frontal white matter from the same AD brain.
  • Figure 14 Shows an autoradiogram and fluorescent micrograph showing the overlap of [I-125]6-OH-BTA-0-3'-I binding to plaques and cerebrovascular amyloid and amyloid deposits stained by the amyloid dye, X-34.
  • Left autoradiogram of [I-125]6-OH- BTA-0-3'-I binding to fresh frozen tissue from post-mortem AD brain. The dark areas show the localization of [I-125]6-OH-BTA-0-3'-I and are outlined in red. The structure of [I- 125]6-OH-BTA-0-3'-I is shown in the lower left.
  • Right The same piece of post-mortem AD brain tissue stained with the amyloid dye, X-34.
  • Figure 15 Shows time-activity curves of the penetration and clearance of radioactivity from three regions of baboon brain following the injection of Compound B (2- (3-[ 18 F]-fluoro-4-methylamino-phenyl)-benzothiazol-6-ol).
  • Figure 16 Shows time-activity curves of the penetration and clearance of radioactivity from baboon cerebellum (reference region devoid of specific binding) following the injection of the radioligands [carbonyl- ⁇ C]WAY100635, [ ⁇ C](+)-McN5652, and [ 18 F]altanserin compared to the behavior of Compound B.
  • Figure 17 Shows time-activity curves of the penetration and clearance of radioactivity from three regions of baboon brain following the injection of Compound C (2-[4-(3- 18 F-fluoro-propylamino)-phenyl]benzothiazol-6-ol).
  • Figure 18 Shows time-activity curves of the penetration and clearance of radioactivity from baboon cerebellum (reference region devoid of specific binding) following the injection of the radioligands [carbonyl- n C]WAY100635, [ ⁇ C](+)-McN5652, and [ 18 F]altanserin compared to the behavior of Compound C.
  • the present invention exploits the ability of Thioflavin compounds and radiolabeled derivatives thereof to cross the blood brain barrier in vivo and bind to A ⁇ deposited in neuritic (but not diffuse) plaques, to A ⁇ deposited in cerebrovascular amyloid, and to the amyloid consisting of the protein deposited in NFT.
  • the present compounds are non- quaternary amine derivatives of Thioflavin S and T which are known to stain amyloid in tissue sections and bind to synthetic A ⁇ in vitro. Kelenyi, J. Histochem. Cytochem. 15: 172 (1967); Burns et al., J. Path. Bad 94:337 (1967); Guntern et al, Experientia 48: 8 (1992); LeNine, Meth. Enzymol 309: 274 (1999).
  • the thioflavin derivatives of the present invention have each of the following characteristics: (1) specific binding to synthetic A ⁇ in vitro and (2) ability to cross a non- compromised blood brain barrier in vivo.
  • thioflavin derivative binding was analyzed using synthetic A ⁇ (l-40) and 2-(4'-[ 11 C]methylamino-phenyl)-benzothiazole ([N-methyl- n C]BTA-l) in phosphate-buffered saline (pH 7.0) or glycine buffer/20% ethanol (pH 8.0), as previously described for Chysamine-G binding. Klunk et al, Neurobiol Aging 15: 691 (1994).
  • Amino acid sequence for A ⁇ (l-40) is as follows:
  • Alkyl refers to a saturated straight or branched chain hydrocarbon radical. Examples include without limitation methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert- butyl, n-pentyl and n-hexyl.
  • Alkenyl refers to an unsaturated straight or branched chain hydrocarbon radical comprising at least one carbon to carbon double bond. Examples include without limitation ethenyl, propenyl, iso-propenyl, butenyl, iso-butenyl, tert-butenyl, n-pentenyl and n-hexenyl.
  • Alkynyl refers to an unsaturated straight or branched chain hydrocarbon radical comprising at least one carbon to carbon triple bond. Examples include without limitation ethynyl, propynyl, iso-propynyl, butynyl, iso-butynyl, tert-butynyl, pentynyl and hexynyl.
  • Alkoxy refers to an alkyl group bonded through an oxygen linkage.
  • Halo refers to a fluoro, chloro, bromo or iodo radical.
  • Radioactive halo refers to a radioactive halo, i.e. radiofluoro, radiochloro, radiobromo or radioiodo.
  • Effective amount refers to the amount required to produce a desired effect.
  • an "effective amount” examples include amounts that enable imaging of amyloid de ⁇ osit(s) in vivo, that yield acceptable toxicity and bioavailability levels for pharmaceutical use, and/or prevent cell degeneration and toxicity associated with fibril formation.
  • “Pharmaceutically acceptable carrier” refers to a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ or portion of the body.
  • a pharmaceutically acceptable material, composition or vehicle such as a liquid or solid filler, diluent, excipient or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ or portion of the body.
  • Each carrier is “acceptable” in the sense of being compatible with the other ingredients of the formulation and suitable for use with the patient.
  • Examples of materials that can serve as a pharmaceutically acceptable carrier include without limitation: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydro
  • “Pharmaceutically acceptable salt” refers to an acid or base salt of the inventive compound, which salt possesses the desired pharmacological activity and is neither biologically nor otherwise undesirable.
  • the salt can be formed with acids that include without limitation acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride hydrobromide, hydroiodide, 2-hydroxyethane- sulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate,
  • Examples of a base salt include without limitation ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine and lysine.
  • the basic nitrogen-contaimng groups can be quarternized with agents including lower alkyl halides such as methyl, ethyl, propyl and butyl chlorides, bromides and iodides; dialkyl sulfates such as dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; and aralkyl halides such as phenethyl bromides.
  • lower alkyl halides such as methyl, ethyl, propyl and butyl chlorides, bromides and iodides
  • dialkyl sulfates such as dimethyl, diethyl, dibutyl and diamyl sulfates
  • long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bro
  • Prodrug refers to a derivative of the inventive compound that undergoes biotransformation, such as metabolism, before exhibiting its pharmacological effect(s).
  • the prodrug is formulated with the objective(s) of improved chemical stability, improved patient acceptance and compliance, improved bioavailability, prolonged duration of action, improved organ selectivity, improved formulation (e.g., increased hydrosolubility), and/or decreased side effects (e.g., toxicity).
  • the prodrug can be readily prepared from the inventive compound using conventional methods, such as that described in BURGER'S MEDICINAL CHEMISTRY AND DRUG CHEMISTRY, 5 th ed., Vol. 1 (1995), pages 172-178 and 949-982.
  • Animal refers to a living organism having sensation and the power of voluntary movement, and which requires for its existence oxygen and organic food. Examples include, without limitation, members of the human, equine, porcine, bovine, murine, canine and feline species. In the case of a human, an "animal” also may be referred to as a "patient.”
  • “Mammal” refers to a warm-blooded vertebrate animal.
  • Treating refers to: (i) preventing a disease, disorder or condition from occurring in an animal that may be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having it;
  • This invention provides radiolabeled benzothiazole derivative compounds as amyloid imaging agents.
  • this invention provides a compound of formula I
  • R 1 is hydrogen, -OH, -NO 2 , -CN, -COOR, -OCH 2 OR, d-Ce alkyl, C 2 -C 6 alkenyl, C 2 - C 6 alkynyl, Ci-C ⁇ alkoxy or halo, wherein one or more of the atoms of R 1 may be a radiolabeled atom;
  • R is Ci-C ⁇ alkyl, wherein one or more of the carbon atoms may be a radiolabeled atom;
  • R ⁇ is hydrogen, a non-radioactive halo or a radioactive halo;
  • R 3 is hydrogen, C ⁇ -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl;
  • R 4 is hydrogen, C C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, wherein the alkyl, alkenyl or alkynyl comprises a radioactive carbon or is substituted with a radioactive halo when R 2 is hydrogen or a non-radioactive halo; provided that when R 1 is hydrogen or -OH, R 2 is hydrogen and R 4 is - ⁇ CH 3 , then R 3 is C 2 -C6 alkyl, C 2 -C6 alkenyl or C 2 -C6 alkynyl; and further provided that when R 1 is hydrogen, R 2 hydrogen and R 4 is -(CH 2 ) 3 18 F, then R 3 is C 2 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl.
  • a radioactive carbon include, without limitation, U C, 13 C and 14 C.
  • radioactive halo examples include, without limitation, 131 L 125 1, 124 1, 123 1, 76 Br, 75 Br, 18 F. In one embodiment, the radioactive halo is 125 L 124 1, 123 I or 18 F. In another embodiment, R 1 is -OH.
  • R 1 is hydrogen, -OH, -CN, -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C ⁇ -C 6 alkoxy or halo;
  • R 2 is hydrogen; and
  • R 4 is Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, wherein the alkyl, alkenyl or alkynyl comprises a radioactive carbon.
  • R 1 is hydrogen, -OH, -CN, -OCH 3 , -CH 3 or -Br;
  • R 3 is hydrogen or -CH 3 ; and
  • R 4 is - n CH 3 .
  • R is a non-radioactive halo or a radioactive halo, wherein the halo is iodo; and R 4 is hydrogen, C ⁇ -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, wherein the alkyl, alkenyl or alkynyl comprises a radioactive carbon when R 2 is a non-radioactive halo.
  • R is -CH 3 ; and the radioactive carbon in R 4 is n C.
  • R 1 is -OH or Ci-C ⁇ alkoxy; R 2 is a radioiodine; and R 3 and R 4 are independently hydrogen or d-C 6 alkyl.
  • R 1 is -OH; R 2 is - 123 I or - 125 I; and R 3 and R 4 are each hydrogen.
  • R is hydrogen, radiobromo, radiochloro or radiofluoro.
  • R 2 is a radiofluoro.
  • R 1 is -OH or Ci-C ⁇ alkoxy; R 2 is 18 F; and R 3 and R 4 are independently hydrogen or C ⁇ -C alkyl.
  • R 1 is -OH; R 3 is hydrogen; and R 4 is -CH 3 .
  • R 4 is C ⁇ -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, wherein the alkyl, alkenyl or alkynyl is substituted with a radioactive halo.
  • R 1 is -OH or Ci-C ⁇ alkoxy
  • R 2 is hydrogen
  • R 3 is hydrogen or C C 6 alkyl
  • R 4 is Ci-C ⁇ alkyl substituted with 18 F.
  • R 1 is -OH
  • R 3 is hydrogen
  • R 4 is -CH 2 CH 2 CH 2 18 F.
  • the inventive compounds bind selectively to amyloid, particularly synthetic A ⁇ in vitro or A ⁇ deposited in neuritic plaques; cross a non- compromised blood-brain barrier in vivo; are bioavailable; and/or are non-toxic.
  • the inventive compounds may be used to determine the presence, location and/or amount of one or more amyloid deposit(s) in an organ or body area, including the brain, of an animal.
  • Amyloid deposit(s) include, without limitation, deposit(s) of A ⁇ .
  • the inventive compound may further be used to correlate amyloid deposition with the onset of clinical symptoms associated with a disease, disorder or condition.
  • the inventive compounds may ultimately be used to, and to diagnose a disease, disorder or condition characterized by amyloid deposition, such as AD, familial AD, Down's syndrome, amyloidosis, Type II diabetes mellitus, and homozygotes for the apolipoprotein E4 allele.
  • the method of this invention determines the presence and location of amyloid deposits in an organ or body area, preferably brain, of a patient.
  • the present method comprises administration of a detectable quantity of a pharmaceutical composition containing an amyloid binding compound of the present invention called a "detectable compound," or a pharmaceutically acceptable water-soluble salt thereof, to a patient.
  • a “detectable quantity” means that the amount of the detectable compound that is administered is sufficient to enable detection of binding of the compound to amyloid.
  • An “imaging effective quantity” means that the amount of the detectable compound that is administered is sufficient to enable imaging of binding of the compound to amyloid.
  • the invention employs amyloid probes which, in conjunction with non-invasive neuroimaging techniques such as magnetic resonance spectroscopy (MRS) or imaging (MRI), or gamma imaging such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT), are used to quantify amyloid deposition in vivo.
  • non-invasive neuroimaging techniques such as magnetic resonance spectroscopy (MRS) or imaging (MRI), or gamma imaging such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)
  • gamma imaging the radiation emitted from the organ or area being examined is measured and expressed either as total binding or as a ratio in which total binding in one tissue is normalized to (for example, divided by) the total binding in another tissue of the same subject during the same in vivo imaging procedure.
  • Total binding in vivo is defined as the entire signal detected in a tissue by an in vivo imaging technique without the need for correction by a second injection of an identical quantity of labeled compound along with a large excess of unlabeled, but otherwise chemically identical compound.
  • a "subject” is a mammal, preferably a human, and most preferably a human suspected of having dementia.
  • the type of detection instrument available is a major factor in selecting a given label.
  • radioactive isotopes and 19 F are particularly suitable for in vivo imaging in the methods of the present invention.
  • the type of instrument used will guide the selection of the radionuclide or stable isotope.
  • the radionuclide chosen must have a type of decay detectable by a given type of instrument.
  • Another consideration relates to the half-life of the radionuclide. The half-life should be long enough so that it is still detectable at the time of maximum uptake by the target, but short enough so that the host does not sustain deleterious radiation.
  • the radiolabeled compounds of the invention can be detected using gamma imaging wherein emitted gamma irradiation of the appropriate wavelength is detected.
  • Methods of gamma imaging include, but are not limited to, SPECT and PET.
  • the chosen radiolabel will lack a particulate emission, but will produce a large number of photons in a 140-200 keV range.
  • the radiolabel will be a positron-emitting radionuclide such as 19 F which will annihilate to form two 511 keV gamma rays which will be detected by the PET camera.
  • amyloid binding compounds/probes are made which are useful for in vivo imaging and quantification of amyloid deposition. These compounds are to be used in conjunction with non-invasive neuroimaging techniques such as magnetic resonance spectroscopy (MRS) or imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT).
  • non-invasive neuroimaging techniques such as magnetic resonance spectroscopy (MRS) or imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT).
  • MRS magnetic resonance spectroscopy
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • the thioflavin derivatives may be labeled with 19 F or 13 C for MRS/MRI by general organic chemistry techniques known to the art. For example, see ADVANCED ORGANIC CHEMISTRY: REACTION, MECHANISMS, AND STRUCTURE, 3 rd ed. (1985),
  • the thioflavin derivatives also may be radiolabeled with F, C, 75 Br, or 76 Br for PET by techniques well known in the art and are described by Fowler, J. and Wolf, A. in POSITRON EMISSION TOMOGRAPHY AND AUTORADIOGRAPHY 391-450 (Raven Press, 1986), the contents of which are hereby incorporated by reference.
  • the thioflavin derivatives also may be radiolabeled with 123 I for SPECT by any of several techniques known to the art. See, e.g., Kulkarni, Int. J. Rad. Appl & Inst. (Part B) 18: 647 (1991), the contents of which are hereby incorporated by reference.
  • the thioflavin derivatives may be labeled with any suitable radioactive iodine isotope, such as, but not limited to 131 1, 125 I, or 123 I, by iodination of a diazotized amino derivative directly via a diazonium iodide, see Greenbaum, F. Am. J. Pharm. 108: 17 (1936), or by conversion of the unstable diazotized amine to the stable triazene, or by conversion of a non-radioactive halogenated precursor to a stable tri-alkyl tin derivative which then can be converted to the iodo compound by several methods well known to the art. See, Satyamurthy and Barrio, J. Org. Chem.
  • the stable tri- alkyl tin derivatives of thioflavin and its analogues are novel precursors useful for the synthesis of many of the radiolabeled compounds within the present invention.
  • these tri-alkyl tin derivatives are one embodiment of this invention.
  • the thioflavin derivatives also may be radiolabeled with known metal radiolabels, such as Technetium-99m ( 99m Tc). Modification of the substituents to introduce ligands that bind such metal ions can be effected without undue experimentation by one of ordinary skill in the radiolabeling art.
  • the metal radiolabeled thioflavin derivative can then be used to detect amyloid deposits. Preparing radiolabeled derivatives of Tc 99m is well known in the art.
  • the methods of the present invention may use isotopes detectable by nuclear magnetic resonance spectroscopy for purposes of in vivo imaging and spectroscopy.
  • Elements particularly useful in magnetic resonance spectroscopy include 19 F and 13 C.
  • Suitable radioisotopes for purposes of this invention include beta-emitters, gamma- emitters, positron-emitters, and x-ray emitters. These radioisotopes include I, I, F, C, 75 Br, and 76 Br. Suitable stable isotopes for use in Magnetic Resonance Imaging (MRI) or Spectroscopy (MRS), according to this invention, include 19 F and 13 C. Suitable radioisotopes for in vitro quantification of amyloid in homogenates of biopsy or post-mortem tissue include 125 1, 14 C, and 3 H.
  • MRI Magnetic Resonance Imaging
  • MRS Spectroscopy
  • the preferred radiolabels are ⁇ C or 18 F for use in PET in vivo imaging, 123 I for use in SPECT imaging, 19 F for MRS/MRI, and 3 H or 1 C for in vitro studies.
  • any conventional method for visualizing diagnostic probes can be utilized in accordance with this invention.
  • the method involves incubating formalin- fixed tissue with a solution of a thioflavin amyloid binding compound of the present invention.
  • the solution is 25-100% ethanol, (with the remainder being water) saturated with a thioflavin amyloid binding compound according to the present invention.
  • the compound stains or labels the amyloid deposit in the tissue, and the stained or labeled deposit can be detected or visualized by any standard method.
  • detection means include microscopic techniques such as bright-field, fluorescence, laser- confocal and cross-polarization microscopy.
  • the method of quantifying the amount of amyloid in biopsy or post-mortem tissue involves incubating a labeled derivative of thioflavin according to the present invention, or a water-soluble, non-toxic salt thereof, with homogenate of biopsy or post-mortem tissue.
  • the tissue is obtained and homogenized by methods well known in the art.
  • the preferred label is a radiolabel, although other labels such as enzymes, chemiluminescent and immunofluorescent compounds are well known to skilled artisans.
  • the preferred radiolabel is 125 1, 14 C or 3 H which is contained in a substituent substituted on one of the compounds of the present formulae described herein.
  • Tissue containing amyloid deposits will bind to the labeled derivatives of the thioflavin amyloid binding compounds of the present invention.
  • the bound tissue is then separated from the unbound tissue by any mechanism known to the skilled artisan, such as filtering.
  • the bound tissue can then be quantified through any means known to the skilled artisan.
  • the units of tissue-bound radiolabeled thioflavin derivative are then converted to units of micrograms of amyloid per 100 mg of tissue by comparison to a standard curve generated by incubating known amounts of amyloid with the radiolabeled thioflavin derivative.
  • the method of distinguishing an Alzheimer's diseased brain from a normal brain involves obtaining tissue from (a) the cerebellum and (b) another area of the same brain, other than the cerebellum, from normal subjects and from subjects suspected of having Alzheimer's disease. Such tissues are made into separate homogenates using methods well known to the skilled artisan, and then are incubated with a radiolabeled thioflavin amyloid binding compound. The amount of tissue which binds to the radiolabeled thioflavin amyloid binding compound is then calculated for each tissue type (e.g. cerebellum, non-cerebellum, normal, abnormal) and the ratio for the binding of non-cerebellum to cerebellum tissue is calculated for tissue from normal and for tissue from patients suspected of having Alzheimer's disease.
  • tissue type e.g. cerebellum, non-cerebellum, normal, abnormal
  • ratios are then compared. If the ratio from the brain suspected of having Alzheimer's disease is above 90% of the ratios obtained from normal brains, the diagnosis of Alzheimer's disease is made.
  • the normal ratios can be obtained from previously obtained data, or alternatively, can be recalculated at the same time the suspected brain tissue is studied.
  • the ability of the present compounds to specifically bind to neurofibrially tangles over amyloid plaques is particularly true at concentrations less than 10 nM, which includes the in vivo concentration range of PET radiotraces. At these low concentrations, which contains only tangles and no plaques, significant binding does not result when compared to control brain tissue containing neither plaques nor tangles. However, incubation of homogenates ofbrain tissue which contains mainly plaques and some tangles with radiolabeled compounds of the formulae described herein, results in a significant increase in binding when compared to control tissue without plaques or tangles. This data suggests the advantage that these compounds are specific for A ⁇ deposits at concentrations less than 10 nM.
  • This invention further provides a method for detecting amyloid deposit(s) in vivo, comprising: (i) administering to an animal an effective amount of an inventive compound, wherein the compound would bind to any amyloid deposit(s) in the animal; and
  • the binding may be detected by any means known in the art.
  • detection means include, without limitation, assays (such as immunometric, calorimetric, densito etric, spectrographic and chromatographic assays), non-invasive neuroimaging techniques (such as magnetic resonance spectroscopy (MRS), magnetic resonance imaging (MRI), and gamma imaging techniques such as single-photon emission computed tomography (SPECT) and positron emission tomography (PET).
  • assays such as immunometric, calorimetric, densito etric, spectrographic and chromatographic assays
  • non-invasive neuroimaging techniques such as magnetic resonance spectroscopy (MRS), magnetic resonance imaging (MRI), and gamma imaging techniques such as single-photon emission computed tomography (SPECT) and positron emission tomography (PET).
  • MRS magnetic resonance spectroscopy
  • MRI magnetic resonance imaging
  • gamma imaging techniques such as single-photon emission computed tomography (SPECT)
  • the radiation emitted from the organ or area being examined is measured and expressed either as total binding or as a ratio in which total binding in one tissue is normalized to (for example, divided by) the total binding in another tissue of the same subject during the same in vivo imaging procedure.
  • Total binding in vivo is defined as the entire signal detected in a tissue by an in vivo imaging technique without the need for correction by a second injection of an identical quantity of labeled compound along with a large excess of unlabeled, but otherwise chemically identical compound.
  • the type of detection instrument available may be a factor in selecting the radioactive halo or carbon isotope.
  • the selected radioisotope should have a type of decay that is detectable by a given instrument.
  • Another consideration relates to the half-life of the radioisotope. The half-life should be long enough such that the radioisotope is still detectable at the time of maximum uptake by the target, but short enough such that the host does not sustain deleterious radiation.
  • the selected radioisotope may lack a particulate emission, but may produce a large number of photons in the 140-200 keV range.
  • the selected radioisotope may be a positron-emitting radioisotope, which annihilates to form two 511 keV gamma rays detectable by a PET camera.
  • Useful radioisotopes include, without limitation: 125 1, 14 C, and 3 H for in vitro quantification of amyloid in homogenates of biopsy or post-mortem tissue; ⁇ C and 18 F for PET in vivo imaging; 123 I for SPECT imaging; 18 F for MRS/MRI; 3 H or 14 C for in vitro studies; and 18 F and 13 C for magnetic resonance spectroscopy.
  • the detecting is effected by gamma imaging, magnetic resonance imaging or magnetic resonance spectroscopy.
  • the gamma imaging is PET or SPECT.
  • inventive compound may be administered by any means known to one of ordinary skill in the art.
  • administration to the animal may be local or systemic and accomplished orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intraarterial, intramuscular, intraperitoneal, intrathecal, intraventricular, intrasternal, intracranial, and intraosseous injection and infusion techniques.
  • the exact administration protocol will vary depending upon various factors including the age, body weight, general health, sex and diet of the patient; the determination of specific administration procedures would be routine to an one of ordinary skill in the art.
  • Dose levels on the order of about 0.001 ⁇ g/kg/day to about 10,000 mg/kg/day of an inventive compound are useful for the inventive methods.
  • the dose level is about 0.001 ⁇ g/kg/day to about 10 ⁇ g/kg/day.
  • the dose level is about 0.01 ⁇ g/kg/day to about 1.0 ⁇ g/kg/day.
  • the dose level is about 0.1 mg/kg/day to about 100 mg/kg/day.
  • the specific dose level for any particular patient will vary depending upon various factors, including the activity and the possible toxicity of the specific compound employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the rate of excretion; the drug combination; and the form of administration.
  • in vitro dosage-effect results provide useful guidance on the proper doses for patient administration. Studies in animal models are also helpful.
  • the considerations for determining the proper dose levels are well known in the art and within the skills of an ordinary physician.
  • Any known administration regimen for regulating the timing and sequence of drug delivery may be used and repeated as necessary to effect treatment in the inventive methods.
  • the regimen may include pretreatment and/or co-administration with additional therapeutic agent(s).
  • the inventive compounds are administered to an animal that is suspected of having or that is at risk of developing a disease, disorder or condition characterized by amyloid deposition.
  • the animal may be an elderly human.
  • the inventive compounds bind to A ⁇ with a dissociation constant (K D ) of about 0.0001 ⁇ M to about 10.0 ⁇ M when measured by binding to synthetic A ⁇ peptide or AD brain tissue.
  • K D dissociation constant
  • This invention further provides a method for detecting amyloid deposit(s) in vitro comprising:
  • the binding may be detected by any means known in the art.
  • detection means include, without limitation, microscopic techniques, such as bright-field, fluorescence, laser-confocal and cross-polarization microscopy.
  • the tissue is biopsy or post-mortem tissue that is formalin-fixed or fresh-frozen.
  • the tissue is homogenized.
  • the inventive compound is in a solution that further comprises 25-99% ethanol, with the remainder of the solution being water.
  • the solution comprises 0-50% ethanol and 0.0001 to 100 ⁇ M of the compound.
  • the method further comprises (iii) separating from the tissue the amyloid deposit(s) bound to the compound; and (iv) quantifying the amyloid deposit(s) bound to the inventive compound.
  • the bound amyloid deposit(s) may be separated from the tissue by any means known in the art, such as filtering.
  • the amount of bound amyloid deposit(s) may be converted to units of ⁇ g of amyloid deposit(s) per 100 mg of tissue by comparison to a standard curve generated by incubating known amounts of amyloid with the inventive compound or pharmaceutically acceptable salt, hydrate, solvate or prodrug.
  • This invention further provides a method for distinguishing an Alzheimer's diseased brain from a normal brain comprising:
  • a diagnosis of Alzheimer's disease may be made if the ratio for an animal suspected of having Alzheimer's disease is, for example, above 90% of the ratio for a normal animal.
  • a "normal" animal is one that is not suffering from Alzheimer's disease.
  • This invention further provides a pharmaceutical composition
  • a pharmaceutical composition comprising:
  • composition may comprise one or more additional pharmaceutically acceptable ingredient(s), including without limitation one or more wetting agent(s), buffering agent(s), suspending agent(s), lubricating agent(s), emulsifier(s), disintegrant(s), absorbent(s), preservative(s), surfactant(s), colorant(s), flavorant(s), sweetener(s) and therapeutic agent(s).
  • additional pharmaceutically acceptable ingredient(s) including without limitation one or more wetting agent(s), buffering agent(s), suspending agent(s), lubricating agent(s), emulsifier(s), disintegrant(s), absorbent(s), preservative(s), surfactant(s), colorant(s), flavorant(s), sweetener(s) and therapeutic agent(s).
  • the composition may be formulated into solid, liquid, gel or suspension form for: (1) oral administration as, for example, a drench (aqueous or non-aqueous solution or suspension), tablet (for example, targeted for buccal, sublingual or systemic abso ⁇ tion), bolus, powder, granule, paste for application to the tongue, hard gelatin capsule, soft gelatin capsule, mouth spray, emulsion and microemulsion; (2) parenteral administration by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution, suspension or sustained-release formulation; (3) topical application as, for example, a cream, ointment, controlled-release patch or spray applied to the skin; (4) intravaginal or intrarectal administration as, for example, a pessary, cream or foam; (5) sublingual administration; (6) ocular administration; (7) transdermal administration; or (8) nasal administration.
  • oral administration as, for example, a drench (aqueous or non-aque
  • the composition is formulated for intravenous administration and the carrier includes a fluid and/or a nutrient replenisher.
  • the composition is capable of binding specifically to amyloid in vivo, is capable of crossing the blood-brain barrier, is non-toxic at appropriate dose levels and/or has a satisfactory duration of effect.
  • the composition comprises about 10 mg of human serum albumin and from about 0.5 to 500 mg of the inventive compound per milliliter of phosphate buffer containing NaCl.
  • K- is hydrogen, -OH, -NO 2 , -CN, -COOR, -OCH OR, Ci-C ⁇ alkyl, C 2 -C 6 alkenyl, C 2 - C 6 alkynyl, C ⁇ -C$ alkoxy or halo, wherein one or more of the atoms of R 1 may be a radiolabeled atom;
  • R is Ci-C ⁇ alkyl, wherein one or more of the carbon atoms may be a radiolabeled atom; is hydrolysed by one of the following two procedures:
  • the 6-substituted -benzothiazole (6.7mmol) is suspended in ethanol (11 mL, anhydrous) and hydrazine (2.4 mL) is added under a nitrogen atmosphere at room temperature.
  • the reaction mixture is heated to reflux for 1 hour.
  • the solvent is evaporated and the residue is dissolved into water (lOmL) and adjusted to a pH of 5 with acetic acid.
  • the precipitate is collected with filtration and washed with water to give the desired product.
  • R 2 is hydrogen, and R 3 and R 4 are independently hydrogen, Ci-C ⁇ alkyl, C 2 - C 6 alkenyl or C -C 6 alkynyl by the following reaction:
  • a mixture of the 5-substituted 2-aminothiophenol (4.0 mmol), the benzoic acid (4.0 mmol), and polyphosphoric acid (PPA) (10 g) is heated to 220° C for 4 hours.
  • the reaction mixture is cooled to room temperature and poured into 10% potassium carbonate solution ( ⁇ 400 mL).
  • the precipitate is collected by filtration under reduced pressure to give the desired product, which can be purified by flash chromatography or recrystallization.
  • the R 2 hydrogen can be substituted with either a non-radioactive halo or a radioactive halo by the following reaction:
  • protecting groups may need to be employed.
  • the 6-hydroxy group is protected as the methanesulfonyl (mesyloxy) derivative.
  • 0.5 ml of 1 M NaOH is added to the eluted solution of radioiodinated intermediate.
  • the mixture is heated at 50 °C for 2 hours.
  • 500 ⁇ L of 1 M acetic acid the reaction mixture is diluted with 40 mL of water and loaded onto a C8 Plus SepPak.
  • the radioiodinated product having a radioactivity of ca.
  • reaction mixture Upon cooling to room temperature, the reaction mixture is poured into water and extracted with ethyl acetate (3 x 10 mL). The organic layers are combined and the solvent is evaporated. The residue is purified by flash column to give the desired 6-substituted dimethylaminophenyl)-benzothiazole.
  • R 4 is Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, wherein the alkyl, alkenyl or alkynyl comprises a radioactive carbon or is substituted with a radioactive halo, the compound can be synthesized by one of the following sequences:
  • [ ⁇ C]carbon dioxide is produced using a CTI/Siemens RDS 112 negative ion cyclotron by irradiation of a nitrogen gas ( 14 N 2 ) target containing 1 % oxygen gas with a 40 ⁇ A beam current of 11 MeV protons for 60 minutes.
  • [ ⁇ C]Carbon dioxide is converted to [ n C]methyl iodide by first reacting it with a saturated solution of lithium aluminum hydride in THF followed by the addition of hydriodic acid at reflux temperature to generate [ ⁇ C]methyl iodide.
  • the [ ⁇ C]methyl iodide is carried in a stream of nitrogen gas to a reaction vial containing the precursor for radiolabeling.
  • the precursor, 6- substituted 2-(4'-aminophenyl)-benzothiazole ( ⁇ 3.7 ⁇ moles), is dissolved in 400 ⁇ L of DMSO. Dry KOH (10 mg) is added, and the 3 mL V-vial is vortexed for 5 minutes. No- carrier-added [ ⁇ C]methyl iodide is bubbled through the solution at 30 mL/minute at room temperature. The reaction is heated for 5 minutes at 95° C using an oil bath.
  • the reaction product is purified by semi-preparative HPLC using a Prodigy ODS-Prep column eluted with 60% acetonitrile/40% triethylammonium phosphate buffer pH 7.2 (flow at 5 mL/minute for 0-7 minutes then increased to 15 mL/minute for 7-30 minutes).
  • the fraction containing [N-methyl- n C] 6-substituted 2-(4'-methylaminophenyl)-benzothiazole (at about 15 min) is collected and diluted with 50 mL of water and eluted through a Waters C18 SepPak Plus cartridge.
  • the C18 SepPak is washed with 10 mL of water, and the product is eluted with 1 mL of ethanol (absolute) into a sterile vial followed by 14 mL of saline.
  • the radiochemical yield averages 17% at EOS based on [ ⁇ C]methyl iodide, and the specific activity averages about 160 GBq/ ⁇ mol (4.3 Ci/ ⁇ mol) at end of synthesis.
  • a cyclotron target containing 0.35 mL of 95% [O-l 8] -enriched water is irradiated with 11 MeV protons at 20 ⁇ A of beam current for 60 minutes, and the contents are transferred to a 5 mL reaction vial containing Kryptof ⁇ x 222 (22.3 mg) and K 2 CO 3 (7.9 mg) in acetonitrile (57 ⁇ L).
  • the solution is evaporated to dryness three times at 110°C under a stream of argon following the addition of 1 mL aliquots of acetonitrile.
  • the product, [F- 18] 6-substituted 2-(4'-(3"-fluoropropylamino)-phenyl)- benzothiazole is eluted at ⁇ 20 minutes in a volume of about 16 mL.
  • the fraction containing [F- 18] 6-substituted 2-(4'-(3"-fluoropropylamino)-phenyl)-benzothiazole is diluted with 50 mL of water and eluted through a Waters C18 SepPak Plus cartridge.
  • the SepPak cartridge is then washed with 10 mL of water, and the product is eluted using 1 mL of ethanol (absol.) into a sterile vial.
  • the precursor, 6- CH 3 O-BTA-l (1.0 mg, 3.7 ⁇ moles), was dissolved in 400 ⁇ L of DMSO. Dry KOH (10 mg) was added, and the 3 mL V-vial was vortexed for 5 minutes. No-carrier-added [ ⁇ C]methyl iodide was bubbled through the solution at 30 mL/minute at room temperature. The reaction was heated for 5 minutes at 95°C using an oil bath.
  • the reaction product was purified by semi-preparative HPLC using a Prodigy ODS-Prep column eluted with 60% acetonitrile/40% triethylammonium phosphate buffer pH 7.2 (flow at 5 mL/minute for 0-7 minutes then increased to 15 mL/minute for 7-30 minutes).
  • the fraction containing N-Methyl- 11 C]2-(4'- Dimethylaminophenyl)-6-methoxy-benzothiazole (at about 15 minutes) was collected and diluted with 50 mL of water and eluted through a Waters C18 SepPak Plus cartridge.
  • the solution was condensed by a nitrogen stream to 300 ⁇ L and the crude product was purified by HPLC on a Phenomenex ODS column (MeCN/TEA buffer, 35:65, pH 7.5, flow rate 0.5 mL/minute up to 4 minutes, 1.0 mL/minute at 4-6 minutes, and 2.0 mL/minute after 6 minutes, retention time 23.6).
  • the collected fractions were loaded onto a C8 Plus SepPak. Elution with 1 mL of ethanol gave ca. 1 mCi of the final radioiodinated product.
  • a cyclotron target containing 0.35 mL of 95% [O- 18] -enriched water was irradiated with 11 MeV protons at 20 ⁇ A of beam current for 60 minutes, and the contents were transferred to a 5 mL reaction vial containing 2 mg Cs 2 CO 3 in acetonitrile (57 ⁇ L).
  • the solution was evaporated to dryness at 110°C under a stream of argon three times using 1 mL aliquots of acetonitrile.
  • the reduction reaction was allowed to proceed for 10 minutes at room temperature (the crude yield for the reduction step was about 40%).
  • To the reaction mixture was added 8 mL of water and 6 mL of diethyl ether, the mixture was shaken and the ether phase separated. The diethyl ether phase was dried under a stream of argon at 120°C.
  • To the reaction vial 700 uL of DMSO was added containing 30 micromoles of CH 3 I and 20 mg of dry KOH. The reaction vial was heated at 120°C for 10 minutes. A solution of 700 uL of 2:1 MeOH/HCl (concentrated) was added and heated for 15 minutes at 120°C.
  • the fraction containing 2-(3- 18 F-fluoro-4-methylamino-phenyl)-benzothiazol-6-ol was diluted with 50 mL of water and eluted through a Waters C18 SepPak Plus cartridge.
  • the SepPak cartridge was then washed with 10 mL of water, and the product was eluted using 1 mL of ethanol (absol.) into a sterile vial.
  • the solution was diluted with 10 mL of sterile normal saline for
  • the radiochemical purity was >99%, and the chemical purity was >90%.
  • the radiochemical identity of 2-(3- F-Fluoro-4-methylamino-phenyl)-benzothiazol- 6-ol was confirmed by reverse phase radio-HPLC utilizing a quality control sample of the final radiochemical product co-injected with a authentic (cold) standard.
  • a cyclotron target containing 0.35 mL of 95% [O- 18] -enriched water was irradiated with 11 MeV protons at 20 ⁇ A of beam current for 60 minutes, and the contents were transferred to a 5 mL reaction vial containing Kryptofix 222 (22.3 mg) and K 2 CO 3 (7.9 mg) in acetonitrile (57 ⁇ L).
  • the solution was evaporated to dryness three times at 110°C under a stream of argon following the addition of 1 mL aliquots of acetonitrile.
  • the fraction containing[F-18]6-HO-BTA-N-PrF was diluted with 50 mL of water and eluted through a Waters C18 SepPak Plus cartridge. The SepPak cartridge was then washed with 10 mL of water, and the product was eluted using 1 mL of ethanol (absol.) into a sterile vial. The solution was diluted with 10 mL of sterile normal saline for intravenous injection into animals.
  • radiochemical and chemical purities of [F-18]6-HO- BTA-N-PrF were assessed by radio-HPLC with UV detection at 350 nm using a Phenomenex Prodigy ODS(3) CI 8 column (5 ⁇ m, 250 x 4.6 mm) eluted with 40% acetonitrile/ 60% 60 mM triethylamine-phosphate buffer (v/v) pH 7.2.
  • the radiochemical purity was >99%, and the chemical purity was >90%.
  • the radiochemical identity of [F-18]6-HO-BTA- N-PrF was confirmed by reverse phase radio-HPLC utilizing a quality control sample of the final radiochemical product co-injected with a authentic (cold) standard.
  • the reaction mixture was loaded onto C8 Plus SepPak and eluted with 2 ml methanol.
  • 0.5 ml of 1 M NaOH was added to the eluted solution of radioiodinated intermediate.
  • the mixture was heated at 50 °C for 2 hours.
  • the reaction mixture was diluted with 40 mL of water and loaded onto a C8 Plus SepPak.
  • the radioiodinated product having a radioactivity of ca. 3 mCi, was eluted off the SepPak with 2 mL of methanol.
  • the solution was condensed by a nitrogen stream to 300 ⁇ L and the crude product was purified by HPLC on a Phenomenex ODS column (MeCN/TEA buffer, 35:65, pH 7.5, flow rate 0.5 mL/min up to 4 min, 1.0 mL/min at 4-6 min, and 2.0 mL/min after 6 min, retention time 23.6).
  • the collected fractions were loaded onto a C8 Plus SepPak. Elution with 1 mL of ethanol gave ca. 1 mCi of the final radioiodinated product.
  • the other 2-(4'-aminophenyl)-benzothiazole derivatives may be synthesized by substituting the appropriate substituted aniline derivative (e.g. 2-, 3-, or 4-methylaniline) and the appropriate 4-nitro-benzoyl chloride derivative (e.g. 2- or 3-methyl-4-mtro-benzoyl chloride).
  • Example 10 Synthesis of BTA Derivatives without substitution
  • 2-(4'-aminophenyl)-benzothiazole derivatives may be synthesized by substituting appropriate 4-nitro-benzoyl chloride derivative (e.g. 2- or 3-methyl-4-nitro-benzoyl chloride) or appropriate 4-dimethylamino- benzoic acid derivative (e.g. 2- or 3-methyl-4-dimethylamino-benzoic acid).
  • 4-nitro-benzoyl chloride derivative e.g. 2- or 3-methyl-4-nitro-benzoyl chloride
  • 4-dimethylamino- benzoic acid derivative e.g. 2- or 3-methyl-4-dimethylamino-benzoic acid
  • Table 1 The data shown in Table 1 indicates that these compounds displayed relatively high affinity for A ⁇ , with Ki values ⁇ 10 nM, and readily entered mouse brain with uptake values >0.4 %ID/g*kg (or >13% ID/g for 30 g animals). Moreover, the 30 min brain radioactivity concentration values were less than 0.1 %ID/g*kg, resulting in 2 min-to-30 min concentration ratios >4.
  • Example 2 Staining amyloid deposits in post-mortem AD and Tg mouse brain
  • Postmortem brain tissue sections from AD brain and an 8 month old transgenic PSl/APP mouse were stained with unlabeled BTA-1.
  • the PSl/APP mouse model combines two human gene mutations known to cause Alzheimer's disease in a doubly transgenic mouse which deposits A ⁇ fibrils in amyloid plaques in the brain beginning as early as 3 months of age. Typical fluorescence micrographs are shown in Figure 8, and the staining of amyloid plaques by BTA-1 in both postmortem AD and PSl/APP brain tissue is clearly visible. Cerebrovascular amyloid also was brightly stained (Fig. 8, right). The other characteristic neuropathological hallmark of AD brain, neurofibrillary tangles (NFT), are more faintly stained by BTA-1 in AD brain (Fig. 8, left). NFT have not been observed in transgenic mouse models of amyloid deposition.
  • NFT neurofibrillary tangles
  • Example 4 Specificity of the Inventive Compounds for Alzheimer plaques over Alzheimer tangles
  • [ 3 H]BTA-1 binding was compared in homogenates from entorhinal cortex (EC), frontal gray and cerebellum from a typical AD brain and a Braak stage II control brain.
  • This control brain had frequent numbers of NFT in the entorhinal cortex (Fig. 5 A), but no neuritic or diffuse plaques in any area of the brain (Fig. 11 C).
  • the NFT numbers in the EC of Cntl 04 were similar to the numbers found in many AD cases (Fig. 1 IB).
  • the extensive NFT pathology in the EC of the Cntl and AD brains, coupled with the low [ 3 H]BTA-1 binding in the EC suggests that either the BTA-1 binding to NFT seen at 100 nM concentrations of BTA-1 does not occur at 1.2 nM, or that, at low nanomolar concentrations, the total absolute amount of [ 3 H]BTA-1 binding to NFT deposits is small in comparison to the amount of [ 3 H]BTA-1 bound to A ⁇ deposits in the plaques and cerebrovascular amyloid of AD frontal gray.
  • the AD brain showed diffuse amyloid plaque deposits in the EC (Fig. 1 IB) which did not appear to produce significant [ 3 H]BTA-1 binding.
  • the frontal cortex had extensive amyloid plaques which were both compact and diffuse and were associated with high levels of [ 3 H]BTA-1 binding (Fig. 1 ID and Table).
  • mice Studies were performed in female Swiss- Webster mice (23-35 g) in accordance with the Guide for the Care and Use of Laboratory Animals adopted by NIH and with the approval of the local Institutional Animal Care and Use Committee.
  • the mice were injected in a lateral tail vein with 0.37-3.7 MBq (10-100 ⁇ Ci) of a high specific activity ( ⁇ 2.0/ ⁇ mol) Compound A, Compound B or Compound C contained in ⁇ 0.10 mL of a solution of 95% isotonic saline and 5% ethanol.
  • the mice were anesthetized and killed by cardiac excision following cardiac puncture to obtain arterial blood samples at 2 minutes or 30 minutes post- injection.
  • the mouse brains were rapidly excised and divided into the cerebellum and the remaining whole brain (including brain stem) fractions.
  • the brain samples were counted in a gamma well-counter, and the counts were decay-corrected to the time of injection relative to 125 I or 18 F standards prepared from the injection solution to determine the percent injected dose (%ID) in the samples.
  • the brain samples were weighed to determine the percent injected dose per gram tissue (%ID/g), and this quantity was multiplied by the whole body weight (in kg) to determine the body-weight normalized radioactivity concentration [(%ID- kg)/g] of each tissue sample.
  • Compound A, Compound B and Compound C displayed relatively high brain entry at early time points and fast clearance at later time points.
  • the radioactivity concentrations (%ID-kg/g) at 2 minutes and 30 minutes and the 2 minutes-to-30 minutes ratios are presented in Table 2 below.
  • Example 7 In vivo baboon imaging studies
  • PET imaging studies in adult baboons were performed with Compound B and Compound C in accordance with the Guide for the Care and Use of Laboratory Animals adopted by NIH and with the approval of the local Institutional Animal Care and Use Committee.
  • the animals Prior to PET imaging, the animals were initially sedated with ketamine (10-15 mg/kg, i.m.), given atropine (0.5 mg, i.m.) to control salivation and heart rate, and intubated.
  • the baboons were subsequently maintained on a ventilator with isofluorane (0.5-1.25%) anesthesia and medical air.
  • Pancuronium bromide was administered as necessary (intravenously, up to 0.06 mg/kg/hour, titrated to effect) to keep the animals immobilized during the study.
  • a femoral artery catheter was inserted to monitor blood pressure and sample arterial blood, and an intravenous catheter was placed in an antecubital vein for radiotracer injection and to administer fluids as necessary throughout the course of the imaging study. Blood pressure, heart and respiratory rates, and expired CO 2 and oxygen saturation levels were monitored continuously during the PET studies.
  • the baseline rectal body temperature ( ⁇ 37°C) was maintained using a heating blanket (Gaymar, Orchard Park, NY) and temperature regulator (Yellow Springs Instruments, Yellow Springs, OH). Prior to scanning, the baboon's head was fixed so that the image planes were acquired approximately parallel to the orbital-meatal line.
  • PET data were acquired using an ECAT HR+ PET scanner (CTI PET Systems,
  • Compound C were administered intravenously over 20 seconds, and a dynamic series of PET scans were acquired over 90 minutes using 26 frames of increasing length (6 x 20 seconds; 4 x 30 seconds; 6 x 60 seconds; 4 x 5 minutes; 6 x 10 minutes). Approximately 185 MBq ( ⁇ 5 mCi) of a high specific activity (>14.8 GBq/ ⁇ mol) Compound B or Compound C was injected in a baboon.
  • An MRI scan was obtained for each baboon using a 1.5T GE Signa scanner (GE Medical Systems, Milwaukee, WI) equipped with a standard head coil.
  • SPGR volumetric spoiled gradient recalled
  • the initial 16 frames (0-9 minutes post-injection) of the dynamic PET images were summed together into images consisting of a single frame.
  • both the MR and summed PET images were edited using the ANALYZE software package (Mayo Clinic, Rochester, MN) to remove extracerebral tissues that could possibly confound the co-registration process.
  • the edited MR images were then coregistered to the summed PET image and resliced to yield MR images in the same spatial orientation and resolution as the summed PET images.
  • the co-registration of MR and PET datasets in the baboon has been demonstrated to be a reliable and robust application of the AIR method.
  • Regions of interest were defined on the coregistered MR image and applied to the dynamic PET datasets to determine regional time-activity data for white matter (cerebral white matter posterior to prefrontal cortex and anterior to lateral ventricles), temporal cortex, cerebellum (cerebellar cortex), and other brain areas (data not shown).
  • the PET time-activity data were converted to units of microcuries per milliliter using a phantom-based calibration factor and were subsequently normalized to the injected dose and body mass of the animal ((%ID-kg)/g).
  • FIG 15 shows a representative PET time-activity curve (TAG) of radioactivity in three brain regions of a baboon following the intravenous injection of Compound B.
  • the TACs indicate excellent brain penetration of radioactivity at early time points (about 0.40 % ID-kg/g, in reasonable agreement to the brain penetration of Compound B in mice at 2 minutes post-injection) in all three regions and relatively rapid clearance of the regional radioactivity from 0-90 minutes post-injection in the brain of this control baboon.
  • Regions of brain containing higher levels of white matter demonstrated somewhat higher (-30%) concentrations of radioactivity at 90 minutes than regions that were dominated by gray matter such as temporal cortex.
  • the concentration of radioactivity in baboon cortex was nearly identical to that in the cerebellar cortex at all time points.
  • the rate of clearance of radioactivity was considerably slower from baboon brain than from mouse brain, with Compound B exhibiting a clearance half-time of about 17 minutes from baboon brain gray matter.
  • the radiotracer Compound B exhibited an early-to-late brain radioactivity concentration in baboon brain of about 4 indicating that only about 25% of the peak maximum radioactivity remained in brain at later time points.
  • Figure 16 compares the cerebellar TACs in baboons of [carbonyl- ⁇ C]WAY100635,
  • Figure 17 shows a representative PET TAC of radioactivity in three brain regions of a baboon following the intravenous injection of Compound C.
  • the TACs indicate excellent brain penetration of radioactivity at early time points (about 0.22 % ID-kg/g, in good agreement to the brain penetration of Compound C in mice at 2 minutes post-injection) in all three regions and relatively rapid clearance of the regional radioactivity from 0-90 minutes post-injection in the brain of this control baboon.
  • Regions ofbrain containing higher levels of white matter demonstrated slightly higher ( ⁇ 10%) concentrations of radioactivity at 90 minutes than regions that were dominated by gray matter such as temporal cortex.
  • the concentration of radioactivity in baboon cortex was nearly identical to that in the cerebellar cortex at all time points.
  • the rate of clearance of radioactivity was considerably slower from baboon brain than from mouse brain, with Compound C exhibiting a clearance half-time of about 10 minutes from baboon brain gray matter.
  • the radiotracer Compound C exhibited an early-to-late brain radioactivity concentration in baboon brain of about 6 indicating that only about 15% of the peak maximum radioactivity remained in brain at later time points.
  • Figure 18 compares the cerebellar TACs in baboons of [carbonyl- ⁇ C]WAYl 00635, [ n C](+)-McN5652, [ 18 F]altanserin and Compound C.
  • the relatively rapid non-specific binding clearance rates of [carbonyl- ⁇ C]WAYl 00635 and [ 18 F]altanserin are important to the success of these PET radioligands for imaging the serotonin 5-HTtA and serotonin 5-HT 2A receptor systems.
  • the relatively slow in vivo clearance of [ u C](+)-McN5652 has limited the usefulness of this radioligand for imaging the serotonin transporter system.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des composés dérivés de benzothiazole, des compositions contenant ces composés, des méthodes de préparation de ces composés et des méthodes d'utilisation de ces composés pour détecter un ou des dépôt(s) amyloïde(s) et pour diagnostiquer une maladie, un trouble ou une affection caractérisé(e) par un ou des dépôt(s) amyloïde(s). Les composés de l'invention sont particulièrement utiles pour le diagnostic et le traitement de patients atteints de maladies dans lesquelles l'accumulation de plaques séniles est courante. Les états maladifs ou les maladies comprennent, mais pas exclusivement, la maladie d'Alzheimer, la maladie d'Alzheimer familiale, le syndrome de Down et les homozygotes pour l'allèle de l'apolipoprotéine E4.
PCT/US2004/007797 2003-03-14 2004-03-15 Composes derives de benzothiazole, compositions et utilisations WO2004083195A1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
ES04720788T ES2393921T3 (es) 2003-03-14 2004-03-15 Compuestos derivados de BENZOTIAZOL, composiciones y usos
PL04720788T PL1611115T3 (pl) 2003-03-14 2004-03-15 Związki pochodne benzotiazolu, kompozycje i zastosowania
AU2004221897A AU2004221897B2 (en) 2003-03-14 2004-03-15 Benzothiazole derivative compounds, compositions and uses
BRPI0408274A BRPI0408274B8 (pt) 2003-03-14 2004-03-15 compostos de ligação de amiloide e composição farmacêutica
CNA2004800125035A CN1784392A (zh) 2003-03-14 2004-03-15 苯并噻唑衍生物化合物、组合物及用途
EP04720788A EP1611115B1 (fr) 2003-03-14 2004-03-15 Composes derives de benzothiazole, compositions et utilisations
JP2006507179A JP4875487B2 (ja) 2003-03-14 2004-03-15 ベンゾチアゾール誘導体化合物、組成物および使用
DK04720788.1T DK1611115T3 (da) 2003-03-14 2004-03-15 Benzothiazolderivatforbindelser, sammensætninger og anvendelser deraf
SI200431952T SI1611115T1 (sl) 2003-03-14 2004-03-15 Spojini benzotiazolnih derivatov, sestavki in uporaba
NO20054674A NO330861B1 (no) 2003-03-14 2005-10-11 Benzotiazolavledede forbindelser, preparater og anvendelser
HK06107502.0A HK1086270A1 (en) 2003-03-14 2006-07-04 Benzothiazole derivative compounds, compositions and uses
AU2011200667A AU2011200667B2 (en) 2003-03-14 2011-02-16 Benzothiazole derivative compounds, compositions and uses
NO20110980A NO20110980L (no) 2003-03-14 2011-07-06 Benzotiazolavledede forbindelser, preparater og anvendelser
FR15C0005C FR15C0005I2 (fr) 2003-03-14 2015-01-21 Composes derives de benzothiazole, compositions et utilisations
NO2015005C NO2015005I1 (no) 2003-03-14 2015-02-18 Flutemetamol (18F)
CY2015007C CY2015007I1 (el) 2003-03-14 2015-03-04 Ενωσεις, συνθεσεις και χρησεις παραγωγων βενζοθειαζολης

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/388,173 US7270800B2 (en) 2000-08-24 2003-03-14 Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US10/388,173 2003-03-14
US10/645,847 US20050043523A1 (en) 2003-08-22 2003-08-22 Benzothiazole derivative compounds, compositions and uses
CA2438032A CA2438032C (fr) 2003-03-14 2003-08-22 Derives de benzothiazole et compositions et utilisations connexes
US10/645,847 2003-08-22

Publications (1)

Publication Number Publication Date
WO2004083195A1 true WO2004083195A1 (fr) 2004-09-30

Family

ID=34426453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/007797 WO2004083195A1 (fr) 2003-03-14 2004-03-15 Composes derives de benzothiazole, compositions et utilisations

Country Status (2)

Country Link
CA (1) CA2438032C (fr)
WO (1) WO2004083195A1 (fr)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113523A1 (fr) * 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. Composés 2-(hétéroaryl)benzoxazoles et dérivés, compositions et procédés servant à stabiliser la transthyrétine et à inhiber le mauvais repliement de la transthyrétine
WO2006014381A3 (fr) * 2004-07-02 2007-01-18 Univ Pittsburgh Imagerie d'amyloides comme marqueur auxiliaire pour l'efficacite de therapies anti-amyloides
WO2007020400A1 (fr) * 2005-08-12 2007-02-22 Ge Healthcare Limited Procédé de fluoration de dérivés anilide et dérivés benzothiazole fluorés en tant qu'agents d’imagerie in vivo
WO2007035405A2 (fr) * 2005-09-16 2007-03-29 University Of Pittsburgh Methode in vivo ou in vitro de detection de depots d'amyloides presentant au moins une proteine amyloidogene
US7214695B2 (en) 2002-12-19 2007-05-08 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2007073200A1 (fr) * 2005-12-21 2007-06-28 Hammersmith Imanet Limited Indicateurs radioactifs pour pet
JP2009519239A (ja) * 2005-12-01 2009-05-14 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション アミロイド生成性タンパク質の造影剤としての同位体標識ベンゾチアゾール化合物
JP2009528271A (ja) * 2006-01-27 2009-08-06 アストラゼネカ・アクチエボラーグ 新規なへテロアリール置換ベンゾチアゾール
EP2121655A1 (fr) * 2007-03-06 2009-11-25 AstraZeneca AB Nouveaux indoles 695 à substitution 2-hétéroaryle
WO2009141137A2 (fr) * 2008-05-23 2009-11-26 Sparkle S.R.L. Nouvelle molécule de [124i][2-(3'-iodo-4'-méthylaminophényle)-6-hydroxy-benzothiazole] pour recherche pet et radiothérapie
US7645881B2 (en) 2004-07-22 2010-01-12 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7670591B2 (en) 2006-06-19 2010-03-02 Astrazeneca Ab Heteroaryl substituted benzoxazoles
WO2010034982A1 (fr) 2008-09-23 2010-04-01 Wista Laboratories Ltd. Ligands pour molécules de la protéine tau agglomérées
US7772256B2 (en) 2007-03-06 2010-08-10 Astrazeneca Ab 2-heteroaryl substituted benzothiophenes and benzofuranes 709
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2010536931A (ja) * 2007-08-30 2010-12-02 ジーイー・ヘルスケア・リミテッド 放射性医薬組成物
US7858803B2 (en) * 2007-04-27 2010-12-28 The General Hospital Corporation Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP2341909A1 (fr) * 2008-10-31 2011-07-13 Merck Sharp & Dohme Corp. Nouveaux azabenzoxazoles substitués
US8013006B2 (en) 2004-07-14 2011-09-06 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US8022075B2 (en) 2005-11-30 2011-09-20 Fujifilm Ri Pharma Co., Ltd. Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
US8530483B2 (en) 2008-05-30 2013-09-10 Merck Sharp & Dohme Corp. Substituted azabenzoxazoles
WO2014032732A1 (fr) 2012-08-28 2014-03-06 Eberhard Karls Universität Tübingen Medizinische Fakultät Benzoxazine halogénée et son utilisation
WO2015051188A1 (fr) * 2013-10-02 2015-04-09 Washington University Molécules hétérocycliques pour l'imagerie biomédicale et leurs applications thérapeutiques
US9249112B2 (en) 2011-09-16 2016-02-02 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor
EP1954287B2 (fr) † 2005-10-31 2016-02-24 Merck Sharp & Dohme Corp. Inhibiteurs de la cetp
CN105579453A (zh) * 2013-09-26 2016-05-11 豪夫迈·罗氏有限公司 作为成像工具的咪唑并[1，2-a]吡啶-7-胺类
WO2017071980A1 (fr) * 2015-10-28 2017-05-04 Ge Healthcare Limited Procédé de production de flutémétamol
US10907197B2 (en) 2014-08-29 2021-02-02 Chdi Foundation, Inc. Probes for imaging huntingtin protein
US11059836B2 (en) 2014-08-29 2021-07-13 Chdi Foundation, Inc. Probes for imaging huntingtin protein

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001014354A1 (fr) * 1999-08-20 2001-03-01 Cancer Research Ventures Limited Composes de 2-arylbenzazole substitues et leur utilisation comme agents antitumoraux
WO2002016333A2 (fr) * 2000-08-24 2002-02-28 University Of Pittsburgh Derives de thioflavine utilises dans un diagnostic antemortem de la maladie d'alzheimer, imagerie in vivo et prevention du depot d'amyloide
WO2002085903A2 (fr) * 2001-04-23 2002-10-31 The Trustees Of The University Of Pennsylvania Inhibiteurs d'agregation de plaque amyloide et agents d'imagerie diagnostique
US20030236391A1 (en) * 2000-08-24 2003-12-25 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001014354A1 (fr) * 1999-08-20 2001-03-01 Cancer Research Ventures Limited Composes de 2-arylbenzazole substitues et leur utilisation comme agents antitumoraux
WO2002016333A2 (fr) * 2000-08-24 2002-02-28 University Of Pittsburgh Derives de thioflavine utilises dans un diagnostic antemortem de la maladie d'alzheimer, imagerie in vivo et prevention du depot d'amyloide
US20030236391A1 (en) * 2000-08-24 2003-12-25 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
WO2002085903A2 (fr) * 2001-04-23 2002-10-31 The Trustees Of The University Of Pennsylvania Inhibiteurs d'agregation de plaque amyloide et agents d'imagerie diagnostique

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"BURGER'S MEDICINAL CHEMISTRY AND DRUG CHEMISTRY", vol. 1, 1995, pages: 172 - 178
"REMINGTON'S PHARMACEUTICAL SCIENCES", 1975, MACK PUBLISHING CO., pages: 1405 - 1412
"THE NATIONAL FORMULARY XIV", 1975, AMERICAN PHARMACEUTICAL ASSOCIATION
CHESTER A M ET AL: "A Lipophilic Thioflavin-T Derivative for Positron Emission Tomography (PET) Imaging of Amyloid", BIOORGANIC AND MEDICINAL CHEMISTRY LETERS, vol. 12, 2002, pages 295 - 298, XP002285913 *
CHESTER A M: "Synthesis and Evaluation of 11C-Labeled 6-Substituted 2-Arylbenzothiazoles as amyloid Imaging Agents", J. MED. CHEM, vol. 46, 19 June 2003 (2003-06-19), pages 2740 - 2754, XP002285914 *
WANG Y ET AL: "SYNTHESIS AND EVALUATION OF 2-(3'-IODO-4'-AMINOPHENYL)-6-HYDROXYBENZO THIAZOLE FOR IN VIVO QUANTITATION OF AMYLOID DEPOSITS IN ALZHEIMER'S DISEASE", JOURNAL OF MOLECULAR NEUROSCIENCE, BIRKHAEUSER, CAMBRIDGE, MA, US, vol. 19, no. 1/2, August 2002 (2002-08-01), pages 11 - 16, XP008031471, ISSN: 0895-8696 *

Cited By (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560488B2 (en) 2002-12-19 2009-07-14 The Scripps Research Institute Methods for treating transthyretin amyloid diseases
US8168663B2 (en) 2002-12-19 2012-05-01 The Scripps Research Institute Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof
US8653119B2 (en) 2002-12-19 2014-02-18 The Scripps Research Institute Methods for treating transthyretin amyloid diseases
US7214696B2 (en) 2002-12-19 2007-05-08 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US7214695B2 (en) 2002-12-19 2007-05-08 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US8338459B2 (en) 2004-05-20 2012-12-25 Foldrx Pharmaceuticals, Inc. Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2005113523A1 (fr) * 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. Composés 2-(hétéroaryl)benzoxazoles et dérivés, compositions et procédés servant à stabiliser la transthyrétine et à inhiber le mauvais repliement de la transthyrétine
US7868033B2 (en) 2004-05-20 2011-01-11 Foldrx Pharmaceuticals, Inc. Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US8147798B2 (en) 2004-07-02 2012-04-03 University of Pittsburgh—of the Commonwealth System of Higher Education Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies
US8580229B2 (en) 2004-07-02 2013-11-12 University of Pittsburgh—of the Commonwealth System of Higher Education Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies
WO2006014381A3 (fr) * 2004-07-02 2007-01-18 Univ Pittsburgh Imagerie d'amyloides comme marqueur auxiliaire pour l'efficacite de therapies anti-amyloides
US8343457B2 (en) 2004-07-02 2013-01-01 University of Pittsburgh—of the Commonwealth System of Higher Education Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies
US8013006B2 (en) 2004-07-14 2011-09-06 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7973069B2 (en) 2004-07-14 2011-07-05 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7645881B2 (en) 2004-07-22 2010-01-12 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CN102731432B (zh) * 2005-08-12 2015-10-21 通用电气健康护理有限公司 酰基苯胺衍生物的氟化方法和作为体内成像剂的苯并噻唑氟化衍生物
RU2419601C2 (ru) * 2005-08-12 2011-05-27 Джи-И Хелткер Лимитед Способ фторирования анилидных производных и фторированные производные бензотиазола в качестве in vivo визуализирующих агентов
US9468694B2 (en) 2005-08-12 2016-10-18 Ge Healthcare Limited Fluorination process
NO341560B1 (no) * 2005-08-12 2017-12-04 Ge Healthcare Ltd Fluorineringsframgangsmåter, nye forbindelser, samt radiofarmasøytiske sett og kassetter
WO2007020400A1 (fr) * 2005-08-12 2007-02-22 Ge Healthcare Limited Procédé de fluoration de dérivés anilide et dérivés benzothiazole fluorés en tant qu'agents d’imagerie in vivo
US8410312B2 (en) 2005-08-12 2013-04-02 Ge Healthcare Limited Fluorination process of anilide derivatives and benzothiazole fluorinate derivatives as in vivo imaging agents
AU2006281216B2 (en) * 2005-08-12 2012-01-19 Ge Healthcare As Fluorination process of anilide derivatives and benzothiazole fluorinate derivatives as in vivo imaging agents
US9126961B2 (en) 2005-08-12 2015-09-08 Ge Healthcare Limited Fluorination process
JP2009507775A (ja) * 2005-08-12 2009-02-26 ジーイー・ヘルスケア・リミテッド インビボ造影剤としてのアニリド誘導体及びベンゾチアゾールフルオリネート誘導体のフッ素化法
CN101355940B (zh) * 2005-09-16 2013-03-27 匹兹堡大学高等教育联邦体系 用于检测具有至少一种促淀粉样变蛋白的淀粉样沉积物的体内或体外方法
CN101355940A (zh) * 2005-09-16 2009-01-28 匹兹堡大学 用于检测具有至少一种促淀粉样变蛋白的淀粉样沉积物的体内或体外方法
WO2007035405A3 (fr) * 2005-09-16 2008-06-05 Univ Pittsburgh Methode in vivo ou in vitro de detection de depots d'amyloides presentant au moins une proteine amyloidogene
JP2009508863A (ja) * 2005-09-16 2009-03-05 ユニバーシティー オブ ピッツバーグ 少なくとも１種のアミロイド形成タンパク質を含むアミロイド沈着物を検出するためのｉｎｖｉｖｏまたはｉｎｖｉｔｒｏ方法
WO2007035405A2 (fr) * 2005-09-16 2007-03-29 University Of Pittsburgh Methode in vivo ou in vitro de detection de depots d'amyloides presentant au moins une proteine amyloidogene
EP1954287B2 (fr) † 2005-10-31 2016-02-24 Merck Sharp & Dohme Corp. Inhibiteurs de la cetp
US8022075B2 (en) 2005-11-30 2011-09-20 Fujifilm Ri Pharma Co., Ltd. Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
JP2009519239A (ja) * 2005-12-01 2009-05-14 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション アミロイド生成性タンパク質の造影剤としての同位体標識ベンゾチアゾール化合物
US8309055B2 (en) 2005-12-21 2012-11-13 Hammersmith Imanet Limited PET radiotracers
WO2007073200A1 (fr) * 2005-12-21 2007-06-28 Hammersmith Imanet Limited Indicateurs radioactifs pour pet
US8163928B2 (en) 2006-01-27 2012-04-24 Astrazeneca Ab Heteroaryl substituted benzothiazoles
JP2009528271A (ja) * 2006-01-27 2009-08-06 アストラゼネカ・アクチエボラーグ 新規なへテロアリール置換ベンゾチアゾール
US8957215B2 (en) 2006-01-27 2015-02-17 Navidea Biopharmaceuticals, Inc. Heteroaryl substituted benzothiazoles
CN101410393B (zh) * 2006-01-27 2012-01-25 阿斯利康(瑞典)有限公司 新颖的杂芳基取代的苯并噻唑
US7670591B2 (en) 2006-06-19 2010-03-02 Astrazeneca Ab Heteroaryl substituted benzoxazoles
EP2121655A4 (fr) * 2007-03-06 2010-09-22 Astrazeneca Ab Nouveaux indoles 695 à substitution 2-hétéroaryle
US7772256B2 (en) 2007-03-06 2010-08-10 Astrazeneca Ab 2-heteroaryl substituted benzothiophenes and benzofuranes 709
EP2121655A1 (fr) * 2007-03-06 2009-11-25 AstraZeneca AB Nouveaux indoles 695 à substitution 2-hétéroaryle
US7858803B2 (en) * 2007-04-27 2010-12-28 The General Hospital Corporation Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders
US8558003B2 (en) 2007-04-27 2013-10-15 The General Hospital Corporation Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders
US8916131B2 (en) 2007-08-30 2014-12-23 Ge Healthcare Limited Radiopharmaceutical composition
RU2475267C2 (ru) * 2007-08-30 2013-02-20 Джи-И Хелткер Лимитед Радиофармацевтическая композиция
JP2010536931A (ja) * 2007-08-30 2010-12-02 ジーイー・ヘルスケア・リミテッド 放射性医薬組成物
WO2009141137A2 (fr) * 2008-05-23 2009-11-26 Sparkle S.R.L. Nouvelle molécule de [124i][2-(3'-iodo-4'-méthylaminophényle)-6-hydroxy-benzothiazole] pour recherche pet et radiothérapie
WO2009141137A3 (fr) * 2008-05-23 2010-02-25 Sparkle S.R.L. Nouvelle molécule de [124i][2-(3'-iodo-4'-méthylaminophényle)-6-hydroxy-benzothiazole] pour recherche pet et radiothérapie
US8530483B2 (en) 2008-05-30 2013-09-10 Merck Sharp & Dohme Corp. Substituted azabenzoxazoles
AU2009295701B2 (en) * 2008-09-23 2014-07-24 Wista Laboratories Ltd. Ligands for aggregated tau molecules
KR20110076956A (ko) * 2008-09-23 2011-07-06 위스타 레보레이토리스 리미티드 응집된 타우 분자에 대한 리간드
US8895313B2 (en) 2008-09-23 2014-11-25 Wista Laboratories Ltd. Ligands for aggregated tau molecules
WO2010034982A1 (fr) 2008-09-23 2010-04-01 Wista Laboratories Ltd. Ligands pour molécules de la protéine tau agglomérées
EP2341909A1 (fr) * 2008-10-31 2011-07-13 Merck Sharp & Dohme Corp. Nouveaux azabenzoxazoles substitués
EP2341909A4 (fr) * 2008-10-31 2012-05-30 Merck Sharp & Dohme Nouveaux azabenzoxazoles substitués
US9249112B2 (en) 2011-09-16 2016-02-02 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor
US9796730B2 (en) 2012-08-28 2017-10-24 Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet Halogenated benzoxazines and their use
WO2014032732A1 (fr) 2012-08-28 2014-03-06 Eberhard Karls Universität Tübingen Medizinische Fakultät Benzoxazine halogénée et son utilisation
CN105579453A (zh) * 2013-09-26 2016-05-11 豪夫迈·罗氏有限公司 作为成像工具的咪唑并[1，2-a]吡啶-7-胺类
CN105579453B (zh) * 2013-09-26 2017-12-22 豪夫迈·罗氏有限公司 作为成像工具的咪唑并[1，2‑a]吡啶‑7‑胺类
WO2015051188A1 (fr) * 2013-10-02 2015-04-09 Washington University Molécules hétérocycliques pour l'imagerie biomédicale et leurs applications thérapeutiques
US10335504B2 (en) 2013-10-02 2019-07-02 Washington University Heterocyclic molecules for biomedical imaging and therapeutic applications
US10907197B2 (en) 2014-08-29 2021-02-02 Chdi Foundation, Inc. Probes for imaging huntingtin protein
US11059836B2 (en) 2014-08-29 2021-07-13 Chdi Foundation, Inc. Probes for imaging huntingtin protein
US12258355B2 (en) 2014-08-29 2025-03-25 Chdi Foundation, Inc. Probes for imaging huntingtin protein
WO2017071980A1 (fr) * 2015-10-28 2017-05-04 Ge Healthcare Limited Procédé de production de flutémétamol
KR20180073581A (ko) * 2015-10-28 2018-07-02 지이 헬쓰케어 리미티드 플루트메타몰의 제조 방법
US10472338B2 (en) 2015-10-28 2019-11-12 Ge Healthcare Limited Method for producing [18F]flutemetamol
RU2733398C2 (ru) * 2015-10-28 2020-10-01 ДжиИ ХЕЛТКЕР ЛИМИТЕД Способ получения флутеметамола
KR102668514B1 (ko) 2015-10-28 2024-05-24 지이 헬쓰케어 리미티드 플루트메타몰의 제조 방법

Also Published As

Publication number Publication date
CA2438032C (fr) 2013-05-07
CA2438032A1 (fr) 2005-02-22

Similar Documents

Publication Publication Date Title
US10137210B2 (en) Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
AU2011200667B2 (en) Benzothiazole derivative compounds, compositions and uses
WO2004083195A1 (fr) Composes derives de benzothiazole, compositions et utilisations
AU2008202626B9 (en) Thioflavin derivatives and their use in diagnosis and therapy of Alzheimer's disease
AU2001286702A1 (en) Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006507179

Country of ref document: JP

Ref document number: 2004221897

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004221897

Country of ref document: AU

Date of ref document: 20040315

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004221897

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004720788

Country of ref document: EP

Ref document number: 2005131872

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 20048125035

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004720788

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0408274

Country of ref document: BR

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载